Skip to content

Myriad Genetics Inc

MYGN· NasdaqCore metricsCIK 899923

In vitro & in vivo diagnostic substances19 peers

Last sale
Nov 12, 2026 · -0.53%
Market cap
$544.84M
95.92M shares
Filings
1,046
$202.70M
Q3 2026−1.6% FY25 yoy
-$43.90M
Q3 2026N/M FY25 yoy
-$39.90M
Q3 2026N/M FY25 yoy
-$76.40M
Q2 2023derivedN/M FY22 yoy
-$0.46
Q3 2026N/M FY25 yoy
$107.10M
Q3 2026+46.1% FY25 yoy
$544.84M
—
0.7×
2.0×
—
—

Twelve months to Sep 30, 2026 · derived

Price

$5.6815.10%$1.01past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$824.50MFY 2025
$851.10M0FY 2015FY 2020FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$824,500,000reported
FY 20242024-12-31$837,600,000reported
FY 20232023-12-31$753,200,000reported
FY 20222022-12-31$678,400,000reported
FY 20212021-12-31$690,600,000reported
FY 20202020-12-31$557,100,000reported
FY 20192019-06-30$851,100,000reported
FY 20182018-06-30$743,700,000 revisedreported
FY 20172017-06-30$728,700,000 revisedreported
FY 20162016-06-30$740,500,000 revisedreported
FY 20152015-06-30$722,500,000 revisedreported

Capital returns

Dividends and buybacks · FY2012 to FY2021
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2021—$0.00$0.00—80.02M sh+4.9%0.0%
FY2020—$0.00$0.00—76.30M sh+2.4%0.0%
FY2019—$50.00M$50.00M—74.50M sh+5.0%66.6%
FY2018—$0.00$0.00—70.92M sh+3.6%0.0%
FY2017—$31.60M$31.60M—68.44M sh−1.0%31.6%

Segments

Revenue by Geography, FY2021 to FY2025FY2021U.S. · FY2021 · $603.70MRoW · FY2021 · $86.90MFY2022U.S. · FY2022 · $591.50MRoW · FY2022 · $86.90MFY2023U.S. · FY2023 · $671.70MRoW · FY2023 · $81.50MFY2024U.S. · FY2024 · $769.50MRoW · FY2024 · $68.10MFY2025U.S. · FY2025 · $768.00MRoW · FY2025 · $56.50M
LineFY2025ShareChange
U.S.$768.00M93%−0.2%
RoW$56.50M6.9%−17.0%
Total$824.50M

From the 10-K filed Feb 24, 2026MYGN

In vitro & in vivo diagnostic substances

Myriad Genetics Inc is the 5th largest of the 20 covered companies the SEC files under this code, by revenue. SIC 2835

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR